A Coruña [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== A Coruña ======

{{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/121_bH1u1bh7zKADazhz0RjK0HF3HNYX9-1NZUwBoY5OHmmktT/?limit=15&utm_campaign=pubmed-2&fc=20240823044424}}

===== Studies =====
Despite the more aggressive behavior of GH&[[PRL]]-[[PitNET]]s compared to [[Somatotroph pituitary neuroendocrine tumor]]s, there were no significant differences in the rate of [[IGF-1]] control between the two drugs ([[pegvisomant]] and [[pasireotide]]) in either patient group.
Both drugs were effective in controlling IGF-1 and [[PRL]] hypersecretion in the tumors studied.
The study found that pegvisomant and pasireotide are both effective treatments for controlling IGF-1 and PRL hypersecretion in patients with GH&PRL-Pit-NETs and GH-Pit-NETs, with no substantial differences in efficacy between the two drugs
((Araujo-Castro M, Biagetti B, Menéndez Torre E, Novoa-Testa I, Cordido F, Pascual-Corrales E, Rodríguez Berrocal V, Guerrero-Pérez F, Vicente A, Percovich Hualpa JC, García-Centeno R, González-Fernández L, Ollero García MD, Irigaray Echarri A, Moure Rodríguez MD, Novo-Rodríguez C, Calatayud M, Villar-Taibo R, Bernabéu I, Alvarez-Escola C, Benítez Valderrama P, Tenorio-Jiménez C, Abellán Galiana P, Venegas E, González-Molero I, Iglesias P, Blanco-Carrera C, Vidal-Ostos De Lara F, de Miguel Novoa P, López Mezquita E, Hanzu FA, Aldecoa I, Aznar S, Lamas C, Aulinas A, Asla Q, Gracia Gimeno P, Recio-Córdova JM, Avilés-Pérez MD, Asensio-Wandosell D, Sampedro-Núñez M, Cámara R, Paja Fano M, Ruz-Caracuel I, Fajardo C, Marazuela M, Puig-Domingo M. [[Pegvisomant]] and [[pasireotide]] in [[PRL]] and [[GH]] co-secreting vs [[GH]]-secreting [[Pit-NET]]s. Endocr Relat Cancer. 2024 May 27;31(7):e240043. doi: 10.1530/ERC-24-0043. PMID: 38713182.)).
----
Glucose metabolism improved in patients with [[acromegaly]] after surgery and 21% of the diabetic patients experienced diabetes remission; being more frequent in patients of older age, and those who experienced surgical cure and those with preserved anterior pituitary function after surgery
((Pascual-Corrales E, Biagetti B, Marazuela M, Asensio-Wandosel D, Rodríguez Berrocal V, Irigaray Echarri A, Novo-Rodríguez C, Calatayud M, Bernabéu I, Alvarez-Escola C, Tenorio-Jiménez C, González Molero I, Iglesias P, Blanco C, de Miguel P, López Mezquita E, Lamas C, Aulinas A, Gracia P, Recio-Córdova JM, Sampedro-Nuñez M, Paja M, Moure Rodríguez MD, Fajardo-Montañana C, Cordido F, Menéndez Torre E, Percovich JC, García-Centeno R, Cámara R, Hanzu FA, Vicente Delgado A, González Fernández L, Guerrero-Pérez F, Ollero García-Agulló MD, Novoa-Testa I, Villar-Taibo R, Benítez Valderrama P, Abellán Galiana P, Venegas Moreno E, Vidal-Ostos De Lara F, Enseñat J, Aznar S, Asla Q, Aviles-Pérez MD, Puig-Domingo M, Araujo-Castro M. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly. Pituitary. 2024 Jun 28. doi: 10.1007/s11102-024-01415-x. Epub ahead of print. PMID: 38940859.)).

===== Department =====

Department of Neurosurgery, Hospital HM Modelo, A Coruña, [[Spain]] (Dr Garcia-Fantini)
----
===2016===
Synergistic Increase of Serum BDNF in Alzheimer Patients Treated with Cerebrolysin and Donepezil: Association with Cognitive Improvement in ApoE4 Cases

===2015===
Vivid Mental Imagery of Biomechanically Impossible Movements Elicited by Cortical Electrostimulation of the Central Region in an Awake Patient